Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Acquired by Nuveen Asset Management LLC

Nuveen Asset Management LLC increased its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Rating) by 803.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 356,687 shares of the company’s stock after purchasing an additional 317,200 shares during the period. Nuveen Asset Management LLC owned 0.54% of Amylyx Pharmaceuticals worth $6,385,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in Amylyx Pharmaceuticals during the third quarter worth approximately $51,000. High Net Worth Advisory Group LLC raised its holdings in Amylyx Pharmaceuticals by 33.3% during the third quarter. High Net Worth Advisory Group LLC now owns 2,000 shares of the company’s stock worth $56,000 after purchasing an additional 500 shares in the last quarter. Metropolitan Life Insurance Co NY raised its holdings in Amylyx Pharmaceuticals by 177.6% during the third quarter. Metropolitan Life Insurance Co NY now owns 2,207 shares of the company’s stock worth $62,000 after purchasing an additional 1,412 shares in the last quarter. Amalgamated Bank raised its holdings in Amylyx Pharmaceuticals by 213.5% during the third quarter. Amalgamated Bank now owns 4,778 shares of the company’s stock worth $135,000 after purchasing an additional 3,254 shares in the last quarter. Finally, Seven Eight Capital LP bought a new stake in Amylyx Pharmaceuticals during the third quarter worth approximately $340,000. Institutional investors own 70.55% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on AMLX shares. Bank of America started coverage on Amylyx Pharmaceuticals in a report on Thursday, January 5th. They issued a “buy” rating and a $50.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Amylyx Pharmaceuticals in a report on Wednesday, February 15th. Finally, Citigroup boosted their price target on shares of Amylyx Pharmaceuticals to $51.00 in a report on Wednesday, November 16th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $48.20.

Amylyx Pharmaceuticals Trading Down 7.5 %

Shares of NASDAQ:AMLX opened at $30.66 on Monday. Amylyx Pharmaceuticals, Inc. has a 1 year low of $6.51 and a 1 year high of $41.93. The firm has a fifty day moving average price of $36.16 and a 200 day moving average price of $34.06.

Insider Buying and Selling

In related news, insider Gina Mazzariello sold 3,586 shares of the company’s stock in a transaction on Friday, February 24th. The shares were sold at an average price of $34.49, for a total value of $123,681.14. Following the completion of the sale, the insider now directly owns 37,414 shares in the company, valued at $1,290,408.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Amylyx Pharmaceuticals news, major shareholder Morningside Venture Investment sold 50,000 shares of the business’s stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $33.75, for a total transaction of $1,687,500.00. Following the completion of the transaction, the insider now owns 7,480,598 shares of the company’s stock, valued at approximately $252,470,182.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Gina Mazzariello sold 3,586 shares of the business’s stock in a transaction on Friday, February 24th. The stock was sold at an average price of $34.49, for a total transaction of $123,681.14. Following the transaction, the insider now directly owns 37,414 shares of the company’s stock, valued at approximately $1,290,408.86. The disclosure for this sale can be found here. Over the last three months, insiders sold 103,586 shares of company stock worth $3,547,681. Corporate insiders own 12.70% of the company’s stock.

About Amylyx Pharmaceuticals

(Get Rating)

Amylyx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.